Part of our Foundation Fundlist WORLDWIDE HEALTHCARE TRUST ORD GBP0.25

Symbol: WWH

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Past Performance

  • 18th Nov 2014 to 18th Nov 20159.97%
  • 18th Nov 2015 to 18th Nov 201619.49%
  • 18th Nov 2016 to 18th Nov 201718.24%
  • 18th Nov 2017 to 18th Nov 20184.21%
  • 18th Nov 2018 to 18th Nov 201910.49%

Key Information

Benchmark MSCI World/Health Care
Sector IT Biotechnology & Healthcare
AMC 0.65%
Total Ongoing Charges 
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing.
1.975%
Gearing 100%
Performance Fee No
Ex-Dividend Date 21 Nov 2019
Dividend Pay Date 9 Jan 2020
Total Dividends - Year to Date26.5
Dividend Yield (%)0.9447

Net Asset Value (Nav)

Latest actual NAV 2,872.69
Latest actual NAV date 14/11/2019
NAV frequency Daily
Premium/Discount -2.36%

Part of our Foundation Fundlist Part of our Foundation Fundlist
WHY IS THIS FUND ON OUR FOUNDATION FUNDLIST?

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here
0.35%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
1.975%
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Company

Business Summary

Worldwide Healthcare Trust PLC is an investment trust. The Trust invests in the global healthcare sector with the objective of achieving a high level of capital growth. The Trust invests in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. The Trust uses gearing and derivative transactions. The Trust invests approximately 60% of the portfolio in larger companies, and at over 20% of the portfolio in smaller companies. Its investment strategies also maintains that over 5% of the portfolio, at the time of acquisition, may be invested in each of debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies. It may invest over of 20% of the portfolio, at the time of acquisition, in companies under sectors, such as healthcare equipment and supplies, healthcare technology, and healthcare providers and services. OrbiMed Capital LLC is the portfolio manager of the Trust.

Financial Summary

BRIEF: For the fiscal year ended 31 March 2019, Worldwide Healthcare Trust PLC revenues increased from £50.8M to £177M. Net income increased from £27.2M to £166.2M. Revenues reflect Movement in investment holding gains in increase from -£41.8M to £131.8M, Overseas Dividends increase of 42% to £13.7M, Fixed Interest Income increase of 69% to £3.8M. Net income benefited from Directors remuneration decrease of 8% to £177K (expense).

Performance

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Cumulative Performance

      1 month3 months6 months1 year3 years5 years
      10.00% 3.31% 10.85% 10.49% 36.14% 78.89%

      Important Information
      Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.

      The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.

      Composition

      Important Documents


      The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.

      Fund Provider Factsheet
      The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
      FUND PROVIDER FACTSHEET
      287,272 bytes PDF Document; last updated 30 Sep 2019
      Key Information Document This document, issued by the product provider, provides key information about an investment product. The information is required by law to help potential investors understand the nature, risks, costs, potential gains and losses of the product and enable comparison with other products.
      KEY INFORMATION DOCUMENT
      282,375 bytes PDF Document; last updated 19 Sep 2019
      Annual Report A report published by the Fund Management Group detailing the progress of the fund during the course of the previous 12 months. The information provided includes a financial statement for the group as a whole.
      ANNUAL REPORT
      2,218,015 bytes PDF Document; last updated 31 Mar 2019
      Semi Annual Report Published periodically through the course of the financial year of the fund, the report provides an overview of the fund's performance and the prospects for the remainder of the year. Included are portfolio changes (i.e. which stocks have been bought and sold), and changes in the geographical breakdown during the course of the previous 12 months.
      SEMI-ANNUAL REPORT
      4,209,206 bytes PDF Document; last updated 30 Sep 2018

      Management Team

      Trevor Polischuk Sven H Borho

      Trevor Polischuk has managed this fund for 11 months.

      Trevor Polischuk Trevor M. Polischuk, Ph.D., is a Public Equity Partner focused on the global pharmaceutical industry. Previously, he worked at Lehman Brothers as a Senior Research Analyst covering the U.S. pharmaceutical industry. Dr. Polischuk began his career at Warner Lambert as a member of the Pharmaceutical Global Marketing Planning team. In this role, he coordinated marketing activities for the second generation gabapentinoid product, Pregabalin. Dr. Polischuk holds a Doctorate in Neuropharmacology & Gross Human Anatomy from Queen's University and an M.B.A. from Queen's University.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Sven H Borho has managed this fund for 24 years and 6 months.

      Sven H Borho Sven H. Borho CFA, is a founding Partner of OrbiMed. Mr. Borho is a senior member of the public equity team and he is a portfolio manager for OrbiMed's public equity and hedge funds. Mr. Borho has played an integral role in the growth of OrbiMed's asset management activities. Mr. Borho started his career in 1991 when he joined OrbiMed's predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. Mr. Borho studied business administration at Bayreuth University in Germany and received an M.Sc. (Econ.), Accounting and Finance, from The London School of Economics; he is a citizen of both Germany and Sweden.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/03/2019

      31/03/2018

      31/03/2017

      31/03/2016

      31/03/2015

      31/03/2014

      Total Revenue 176.96 50.85 264.24 -79.86 364.58 149.33
      Gross profit 168.52 29.25 250.24 -82.79 340.62 133.93
      Operating Profit/Loss 167.96 28.71 249.52 -83.55 339.80 133.18
      Profit Before Tax 167.96 28.71 249.52 -83.55 339.80 133.18
      Profit After Tax 166.24 27.18 248.37 -84.63 338.69 132.12
      Equity Holders of Parent Company 166.24 27.18 248.37 -84.63 338.69 132.12
      Minority Interest NIL NIL NIL NIL NIL NIL


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/03/2019

      31/03/2018

      31/03/2017

      31/03/2016

      31/03/2015

      31/03/2014

      Total Non-Current Assets 1,390.58 1,294.03 1,191.97 935.67 1,091.31 713.46
      Total Current Assets 63.26 17.12 17.84 20.84 11.78 25.31
      Total Assets 1,453.84 1,311.15 1,209.81 956.51 1,103.09 738.77
      Total Liabilities NIL NIL NIL NIL NIL NIL
      Total Net Assets NIL NIL NIL NIL NIL NIL
      Shareholders Funds 1,432.09 1,202.19 1,100.90 881.76 982.51 636.19
      Minority Interests NIL NIL NIL NIL NIL NIL
      Total Equity NIL NIL NIL NIL NIL NIL

      Investment involves risk. You may get back less than invested.